The gender difference in treatment and mortality regarding the big infarctions - STEMI - has not diminished from 1998-2000 to 2004-2006, in spite of an increased attention to gender differences in treatment of myocardial infarctions, focus on adherence to guidelines and a change in predominant therapy.
In case of STEMI, a coronary artery is completely occluded and acute opening of the artery is therefore the most important treatment. This so called reperfusion treatment can be done in two different ways - with fibrinolytic drugs or via coronary artery catheterisation with primary percutaneous coronary intervention, PCI. Historically, treatment with fibrinolytics has dominated, but since the beginning of the 21th century, primary PCI has become the preferred treatment. Studies from the fibrinolytic era found gender differences in outcome, including a higher risk of bleeding and death in women than in men, and women got less reperfusion therapy during that time. Our hypothesis was that the previously found gender difference in reperfusion therapy rate would have diminished since the shift from fibrinolytics to primary PCI.
In our study, a total of 30077 STEMI patients were admitted during two inclusion periods, 15697 (35% women) in 1998-2000 when fibrinolytics was the dominating reperfusion therapy and 14380 (35% women) in 2004-2006 when primary PCI was the dominating reperfusion therapy. Among patients treated with reperfusion therapy, 9% were treated with primary PCI in the early period, compared to 68% in the late period. Mean age was the same in the two time periods.
We found that the gender gap in reperfusion treatment has not diminished between the early and the late periods - instead it increased. In the early period, 70.9% of the men compared to 63.1% of the women, were treated with reperfusion therapy. The corresponding figures in the late period were 75.3% of the men and 63.6% of the women. After adjustment for women's higher age and co-morbidity, they still had 20% less chance of getting this therapy in the late time period.
Also, all other evidence-based therapies were prescribed more rarely to women in both time episodes and the gender gap has actually increased between the periods regarding some therapies, to the disadvantage of women. Neither had the gender gap in outcome diminished between the early and the late time episodes.
In conclusion, to our surprise and in spite of the gender debate and focus on adherence to guidelines in the last decade, the treatment gender gap did not diminish between these two time periods - it in fact increased.
Neither did the gender difference in outcome diminish. As the RIKS-HIA register includes all patients cared for at CCUs in Sweden, we are confident that we can draw firm conclusions about gender differences in the European STEMI population in general. We have shown that adherence to guidelines needs to be increased in women with STEMI which could probably improve their prognosis.